Series A Funding Awarded to Nob Hill Therapeutics to Advance...

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our MedTech Outlook Advisory Board.

Series A Funding Awarded to Nob Hill Therapeutics to Advance Breakthrough Respiratory Technologies

Nob Hill Therapeutics, Inc. (NHT), an early-stage company developing innovative treatments for lung diseases, has secured $3 million in Series A funding led by Tramway Venture Partners, with participation from TCA Venture Group and VIC Technology Venture Development. This investment will advance NHT’s high-dose respiratory technologies and pre-investigational new drug studies. Chris Japp from Tramway Venture Partners will join NHT’s Board of Directors while Sima Ghafari from TCA Venture Group will serve as a Board Observer.

See NHT’s August 6 press release, “Nob Hill Therapeutics Secures Series A Funding to Advance Breakthrough Respiratory Technologies,” reposted below and on the Cision PRWeb Website here: https://www.prweb.com/releases/nob-hill-therapeutics-secures-series-a-funding-to-advance-breakthrough-respiratory-technologies-302213983.html

Nob Hill Therapeutics Secures Series A Funding to Advance Breakthrough Respiratory Technologies

Funding Led by Tramway Venture Partners Includes Key Appointments to the Board and Accelerates the Development of High-Dose Lung Delivery Solutions.

ALBUQUERQUE, N.M., — Nob Hill Therapeutics (NHT) an early-stage pulmonary medical device and therapeutics company, today announced the first close of a $3 million Series A financing round. The round was led by new investor Tramway Venture Partners and included investments from TCA Venture Group and VIC Technology Venture Development (which founded NHT). In connection with the financing, Chris Japp, Managing Partner of Tramway Venture Partners, will join Nob Hill’s Board of Directors. Sima Ghafari of TCA Venture Group will join as a Board Observer.

Nob Hill Therapeutics, Inc. (NHT) is developing new technologies and therapies for lung-related diseases that cannot be effectively treated today. The funds will support continued development of Nob Hill’s high-dose respiratory technology and therapeutics, including pre-IND studies.

Chris Japp said, “We are excited to work with the Nob Hill Therapeutics team and add them to the Tramway portfolio. Their respiratory technology and therapeutics have the potential to help millions of patients that currently do not have good treatment options for lung-related diseases.”

Noel Greenberger, CEO of NHT, added, “We continue to advance our goal of being the leading provider of high-dose lung delivery solutions. We look forward to working with our investors, who bring not only years of medical device and therapeutic experience, but pulmonary expertise too. With our investors’ support, we can accelerate our drive to address some of the most challenging pulmonary diseases.”

NHT has a patent-protected inhalation device technology capable of delivering high therapeutic doses directly to the lung. It is suitable for patients of all ages and inhalation capabilities, including patients with compromised lung function.

The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.